Skip to main content

Table 1 Clinical characteristics and genotype of patients with Gaucher disease and gastrointestinal mucosal involvement

From: Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy

 

Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

Case 7

Age at onset

33 years

33 years

fetal period

fetal period

11 months

10 years

39 years

Type

non-neuronopathic

non-neuronopathic

acute neuronopathic

acute neuronopathic

acute neuronopathic

non-neuronopathic

non-neuronopathic

Involvement sites

duodenal mucosa

duodenal mucosa

stomach, small intestine

gastrointestinal (GI) tract

gastric mucosa

colon

GI tract (from stomach to rectum)

Symptoms

severe dyspepsia, weight loss

mild dyspepsia, weight loss

hydrops fetalis

colloid baby

massive GI bleeding

hematochezia, cured

GI bleeding

Treatment

SRT (eliglustat tartrate)

ERT

none

none

high dose of ERT, PPI

endoscopic sclerotherapy, polypectomy

none

Outcome

improving

persistent

expired

expired

Expired

cured

expired

GBA gene

p.R48W, p.R257Q

p.R257Q,

p. P171fsX21

p.R120W, p.S196P

Homozygous for p.L483P

NA

NA

Age at splenectomy

5 years

5 years

ND

ND

ND

4 years

ND

Reference

present cases

[9]

[12]

[13]

[14]

[15]

  1. NA not available, SRT substrate reduction therapy, ERT enzyme replacement therapy, PPI proton pump inhibitor, ND not done